Cargando…

Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell–Mediated Tumor Therapy

PURPOSE: The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity. Then, this study aimed to determine the inhibitory effects of this peptide on cancer immune escape by coculturin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yilei, Huang, Hongxing, Liu, Yin, Wang, Zhanghao, Wang, Lili, Wang, Quanxiao, Zhang, Yan, Wang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016318/ https://www.ncbi.nlm.nih.gov/pubmed/34352997 http://dx.doi.org/10.4143/crt.2021.424

Ejemplares similares

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Approaching infinite affinity through engineering of peptide–protein interaction
por: Keeble, Anthony H., et al.
Publicado: (2019)

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
por: Zhu, Qiang, et al.
Publicado: (2023)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma
por: Wu, Leyang, et al.
Publicado: (2022)

PPI-Affinity: A Web Tool for the Prediction and Optimization of Protein–Peptide and Protein–Protein Binding Affinity
por: Romero-Molina, Sandra, et al.
Publicado: (2022)

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors
por: Geng, Lingling, et al.
Publicado: (2015)

Tunable Fullerene Affinity of Cages, Bowls and Rings Assembled by Pd(II) Coordination Sphere Engineering
por: Chen, Bin, et al.
Publicado: (2019)

Integrated analysis of ceRNA network and tumor-infiltrating immune cells in esophageal cancer
por: Chen, Yuhua, et al.
Publicado: (2021)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Magneto-nanosensor platform for probing low-affinity protein–protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction
por: Lee, Jung-Rok, et al.
Publicado: (2016)

Modulating Uranium Binding Affinity in Engineered Calmodulin EF-Hand Peptides: Effect of Phosphorylation
por: Pardoux, Romain, et al.
Publicado: (2012)

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2
por: Silver, Aliyah B., et al.
Publicado: (2023)

Biopanning of mouse bone marrow mesenchymal stem cell affinity for cyclic peptides
por: Wang, Guozong, et al.
Publicado: (2019)

Expanding RNA binding specificity and affinity of engineered PUF domains
por: Zhao, Yang-Yang, et al.
Publicado: (2018)

Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint
por: Hu, Kuan, et al.
Publicado: (2020)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
por: Liu, Dan, et al.
Publicado: (2023)

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
por: Wang, Jun, et al.
Publicado: (2017)

Mathematical modeling and stochastic simulations suggest that low-affinity peptides can bisect MHC1-mediated export of high-affinity peptides into “early”- and “late”-phases
por: Kundu, Siddhartha
Publicado: (2021)

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
por: Bailey, Christopher M., et al.
Publicado: (2022)

Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification
por: Ma, Yi, et al.
Publicado: (2017)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Related parameters of affinity and stability prediction of HLA-A*2402 restricted antigen peptides based on molecular docking
por: Huang, Changxin, et al.
Publicado: (2021)

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation
por: Fung, Ella, et al.
Publicado: (2021)

Combinatorial Optimization of Cystine-Knot Peptides towards High-Affinity Inhibitors of Human Matriptase-1
por: Glotzbach, Bernhard, et al.
Publicado: (2013)

Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep)
por: Ngambenjawong, Chayanon, et al.
Publicado: (2016)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery
por: Tang, Shaogeng, et al.
Publicado: (2019)

V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins
por: Zhou, Caihong, et al.
Publicado: (2013)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors
por: Huang, Tinglei, et al.
Publicado: (2021)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

Cell Penetrating Peptide-Based Self-Assembly for PD-L1 Targeted Tumor Regression
por: Guo, Feng, et al.
Publicado: (2021)

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms
por: Presotto, Danilo, et al.
Publicado: (2017)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Systematic Modeling, Prediction, and Comparison of Domain–Peptide Affinities: Does it Work Effectively With the Peptide QSAR Methodology?
por: Liu, Qian, et al.
Publicado: (2022)

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)
por: Du, Jiangfeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r3s2vvsaks2of4cj64vu1md5d8